Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines

References

• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-20. doi:10.1056/NEJMoa0908492. PMID:19843557
   PubMed Web of Science ®Google Scholar
• Wang S, Kennedy JS, West K, Montefiori DC, Coley S, Lawrence J, Shen S, Green S, Rothman AL, Ennis FA, et al. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine. 2008;26(31):3947-57. doi:10.1016/j.vaccine.2007.12.060. PMID:18724414
   PubMed Web of Science ®Google Scholar
• Bansal A, Jackson B, West K, Wang S, Lu S, Kennedy JS, Goepfert PA. Multifunctional T-cell characteristics induced by a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine regimen given to healthy adults are dependent on the route and dose of administration. J Virol. 2008;82(13):6458-69. doi:10.1128/JVI.00068-08. PMID:18448544
   PubMed Web of Science ®Google Scholar
• Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology. 2006;350(1):34-47. doi:10.1016/j.virol.2006.02.032. PMID:16616287
   PubMed Web of Science ®Google Scholar
• Wang S, Arthos J, Lawrence JM, Van Ryk D, Mboudjeka I, Shen S, Chou TH, Montefiori DC, Lu S. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol. 2005;79(12):7933-7. doi:10.1128/JVI.79.12.7933-7937.2005. PMID:15919951
   PubMed Web of Science ®Google Scholar
• Vaine M, Wang S, Hackett A, Arthos J, Lu S. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine. 2010;28(17):2999-3007. doi:10.1016/j.vaccine.2010.02.006. PMID:20170767
   PubMed Web of Science ®Google Scholar
• Vaine M, Wang S, Liu Q, Arthos J, Montefiori D, Goepfert P, McElrath MJ, Lu S. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One. 2010;5(11):e13916. doi:10.1371/journal.pone.0013916. PMID:21085486
   PubMed Web of Science ®Google Scholar
• Vaine M, Wang S, Crooks ET, Jiang P, Montefiori DC, Binley J, Lu S. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol. 2008;82(15):7369-78. doi:10.1128/JVI.00562-08. PMID:18495775
   PubMed Web of Science ®Google Scholar
• Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79(16):10108-25. doi:10.1128/JVI.79.16.10108-10125.2005. PMID:16051804
   PubMed Web of Science ®Google Scholar
• Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006;80(23):11776-90. doi:10.1128/JVI.01730-06. PMID:16971434
   PubMed Web of Science ®Google Scholar
• Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Wood B, Daniels MG, et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010;84(3):1439-52. doi:10.1128/JVI.02108-09. PMID:19939925
   PubMed Web of Science ®Google Scholar
• Gao F, Morrison SG, Robertson DL, Thornton CL, Craig S, Karlsson G, Sodroski J, Morgado M, Galvao-Castro B, von Briesen H, et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID networks for HIV isolation and characterization. J Virol. 1996;70(3):1651-67. PMID:8627686
   PubMed Web of Science ®Google Scholar
• Peters PJ, Bhattacharya J, Hibbitts S, Dittmar MT, Simmons G, Bell J, Simmonds P, Clapham PR. Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J Virol. 2004;78(13):6915-26. doi:10.1128/JVI.78.13.6915-6926.2004. PMID:15194768
   PubMed Web of Science ®Google Scholar
• Peters PJ, Duenas-Decamp MJ, Sullivan WM, Clapham PR. Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues. J Neuroimmune Pharmacol. 2007;2(1):32-41. doi:10.1007/s11481-006-9042-2. PMID:18040824
   PubMed Web of Science ®Google Scholar
• Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, Nathanson N, Srinivasan A. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol. 1992;66(12):7517-21. PMID:1433527
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, Miralles GD, Fauci AS. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis. 1996;173(1):60-7. PMID:8537683
   PubMed Web of Science ®Google Scholar
• Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, Taylor J, Levy R, Murphy RL, Wolinsky SM, et al. Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol. 2003;77(22):12336-45. PMID:14581570
   PubMed Web of Science ®Google Scholar
• Ohagen A, Ghosh S, He J, Huang K, Chen Y, Yuan M, Osathanondh R, Gartner S, Shi B, Shaw G, et al. Apoptosis induced by infection of primary brain cultures with diverse human immunodeficiency virus type 1 isolates: Evidence for a role of the envelope. J Virol. 1999;73(2):897-906. PMID:9882290
   PubMed Web of Science ®Google Scholar
• Schubert U, Clouse KA, Strebel K. Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol. 1995;69(12):7699-711. PMID:7494279
   PubMed Web of Science ®Google Scholar
• Ghorpade A, Nukuna A, Che M, Haggerty S, Persidsky Y, Carter E, Carhart L, Shafer L, Gendelman HE. Human immunodeficiency virus neurotropism: An analysis of viral replication and cytopathicity for divergent strains in monocytes and microglia. J Virol. 1998;72(4):3340-50. PMID:9525661
   PubMed Web of Science ®Google Scholar
• McCutchan FE, Carr JK, Bajani M, Sanders-Buell E, Harry TO, Stoeckli TC, Robbins KE, Gashau W, Nasidi A, Janssens W, et al. Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria. Virology. 1999;254(2):226-34. doi:10.1006/viro.1998.9505. PMID:9986789
   PubMed Web of Science ®Google Scholar
• Ivey-Hoyle M, Culp JS, Chaikin MA, Hellmig BD, Matthews TJ, Sweet RW, Rosenberg M. Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4. Proc Natl Acad Sci U S A. 1991;88(2):512-6. doi:10.1073/pnas.88.2.512. PMID:1899141
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, Johnston MN, Gao F, Walker BD, Rosenberg ES. Viremia control despite escape from a rapid and potent autologous neutralizing antibody response after therapy cessation in an HIV-1-infected individual. J Immunol. 2003;170(7):3906-14. doi:10.4049/jimmunol.170.7.3906. PMID:12646660
   PubMed Web of Science ®Google Scholar
• Westervelt P, Gendelman HE, Ratner L. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci U S A. 1991;88(8):3097-101. doi:10.1073/pnas.88.8.3097. PMID:2014229
   PubMed Web of Science ®Google Scholar
• Theodore TS, Englund G, Buckler-White A, Buckler CE, Martin MA, Peden KW. Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res Hum Retroviruses. 1996;12(3):191-4. doi:10.1089/aid.1996.12.191. PMID:8835195
   PubMed Web of Science ®Google Scholar
• Rodenburg CM, Li Y, Trask SA, Chen Y, Decker J, Robertson DL, Kalish ML, Shaw GM, Allen S, Hahn BH, et al. Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents. AIDS Res Hum Retroviruses. 2001;17(2):161-8. doi:10.1089/08892220150217247. PMID:11177395
   PubMed Web of Science ®Google Scholar
• Novitsky VA, Montano MA, McLane MF, Renjifo B, Vannberg F, Foley BT, Ndung'u TP, Rahman M, Makhema MJ, Marlink R, et al. Molecular cloning and phylogenetic analysis of human immunodeficiency virus type 1 subtype C: A set of 23 full-length clones from Botswana. J Virol. 1999;73(5):4427-32. PMID:10196340
   PubMed Web of Science ®Google Scholar
• Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol. 2004;78(23):13232-52. doi:10.1128/JVI.78.23.13232-13252.2004. PMID:15542675
   PubMed Web of Science ®Google Scholar
• Lu S. Heterologous prime-boost vaccination. Curr Opin Immunol. 2009;21(3):346-51. doi:10.1016/j.coi.2009.05.016. PMID:19500964
   PubMed Web of Science ®Google Scholar
• Huang Z, Chou A, Tanguay J, Shen S, Mboudjeka I, Chou TH, Lu S, Wang S. Levels of N-linked glycosylation on the V1 loop of HIV-1 Env proteins and their relationship to the antigenicity of Env from primary viral isolates. Curr HIV Res. 2008;6(4):296-305. doi:10.2174/157016208785132518. PMID:18691028
   PubMed Web of Science ®Google Scholar
• Bradley T, Pollara J, Santra S, Vandergrift N, Pittala S, Bailey-Kellogg C, Shen X, Parks R, Goodman D, Eaton A, et al. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat Commun. 2017;8:15711. doi:10.1038/ncomms15711. PMID:28593989
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-86. doi:10.1056/NEJMoa1113425. PMID:22475592
   PubMed Web of Science ®Google Scholar
• Burnett RC, Hanly WC, Zhai SK, Knight KL. The IgA heavy-chain gene family in rabbit: Cloning and sequence analysis of 13 C alpha genes. EMBO J. 1989;8(13):4041-7. PMID:2512120
   PubMed Web of Science ®Google Scholar
• Duenas-Decamp MJ, Clapham PR. HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12. J Virol. 2010;84(18):9608-12. doi:10.1128/JVI.00185-10. PMID:20610714
   PubMed Web of Science ®Google Scholar
• O'Connell O, Repik A, Reeves JD, Gonzalez-Perez MP, Quitadamo B, Anton ED, Duenas-Decamp M, Peters P, Lin R, Zolla-Pazner S, et al. Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism. J Virol. 2013;87(1):187-98. doi:10.1128/JVI.01834-12. PMID:23055568
   PubMed Web of Science ®Google Scholar
• Peters PJ, Duenas-Decamp MJ, Sullivan WM, Brown R, Ankghuambom C, Luzuriaga K, Robinson J, Burton DR, Bell J, Simmonds P, et al. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology. 2008;5:5. doi:10.1186/1742-4690-5-5. PMID:18205925
   PubMed Web of Science ®Google Scholar
• Vaine M, Duenas-Decamp M, Peters P, Liu Q, Arthos J, Wang S, Clapham P, Lu S. Two closely related Env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates. J Virol. 2011;85(10):4927-36. doi:10.1128/JVI.00081-11. PMID:21411542
   PubMed Web of Science ®Google Scholar
• Bricault CA, Kovacs JM, Nkolola JP, Yusim K, Giorgi EE, Shields JL, Perry J, Lavine CL, Cheung A, Ellingson-Strouss K, et al. A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component. J Virol. 2015;89(5):2507-19. doi:10.1128/JVI.03331-14. PMID:25540368
   PubMed Web of Science ®Google Scholar
• Wang S, Farfan-Arribas DJ, Shen S, Chou TH, Hirsch A, He F, Lu S. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine. 2006;24(21):4531-40. doi:10.1016/j.vaccine.2005.08.023. PMID:16140431
   PubMed Web of Science ®Google Scholar
• Kayman SC, Wu Z, Revesz K, Chen H, Kopelman R, Pinter A. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains. J Virol. 1994;68(1):400-10. PMID:7504740
   PubMed Web of Science ®Google Scholar
• Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, Zhou T, Schmidt SD, Wu L, Xu L, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010;329(5993):856-61. doi:10.1126/science.1187659. PMID:20616233
   PubMed Web of Science ®Google Scholar
• Julien JP, Sok D, Khayat R, Lee JH, Doores KJ, Walker LM, Ramos A, Diwanji DC, Pejchal R, Cupo A, et al. Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog. 2013;9(5):e1003342. doi:10.1371/journal.ppat.1003342. PMID:23658524
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, Wang SK, Ramos A, Chan-Hui PY, Moyle M, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466-70. doi:10.1038/nature10373. PMID:21849977
   PubMed Web of Science ®Google Scholar
• Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996;70(2):1100-8. PMID:8551569
   PubMed Web of Science ®Google Scholar
• Spurrier B, Sampson J, Gorny MK, Zolla-Pazner S, Kong XP. Functional implications of the binding mode of a human conformation-dependent V2 monoclonal antibody against HIV. J Virol. 2014;88(8):4100-12. doi:10.1128/JVI.03153-13. PMID:24478429
   PubMed Web of Science ®Google Scholar
• Chen Y, Vaine M, Wallace A, Han D, Wan S, Seaman MS, Montefiori D, Wang S, Lu S. A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. J Virol. 2013;87(18):10232-43. doi:10.1128/JVI.00837-13. PMID:23864612
   PubMed Web of Science ®Google Scholar
• Pan R, Chen Y, Vaine M, Hu G, Wang S, Lu S, Kong XP. Structural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding. Emerg Microbes Infect. 2015;4(7):e44. doi:10.1038/emi.2015.44. PMID:26251831
   PubMed Web of Science ®Google Scholar
• Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, Binley JM, Stamatatos L. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: Comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol. 2006;80(17):8745-62. doi:10.1128/JVI.00956-06. PMID:16912322
   PubMed Web of Science ®Google Scholar
• Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, Jiang P, de Vries RP, Wiley C, Zharkikh I, Schülke N, et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology. 2007;366(2):245-62. doi:10.1016/j.virol.2007.04.033. PMID:17580087
   PubMed Web of Science ®Google Scholar
• Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100(7):4144-9. doi:10.1073/pnas.0630530100. PMID:12644702
   PubMed Web of Science ®Google Scholar
• Agwale SM, Forbi JC, Notka F, Wrin T, Wild J, Wagner R, Wolf H. Broad antibody mediated cross-neutralization and preclinical immunogenicity of new codon-optimized HIV-1 clade CRF02_AG and G primary isolates. PLoS One. 2011;6(8):e23233. doi:10.1371/journal.pone.0023233. PMID:21829720
   PubMed Web of Science ®Google Scholar
• Imholte GC, Sauteraud R, Korber B, Bailer RT, Turk ET, Shen X, Tomaras GD, Mascola JR, Koup RA, Montefiori DC, et al. A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. J Immunol Methods. 2013;395(1–2):1-13. doi:10.1016/j.jim.2013.06.001. PMID:23770318
   PubMed Web of Science ®Google Scholar
• 'Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses. 2012;28(11):1444-57. doi:10.1089/aid.2012.0103. PMID:23035746
   PubMed Web of Science ®Google Scholar
• Joachimiak MP, Weisman JL, May B. JColorGrid: Software for the visualization of biological measurements. BMC Bioinformatics. 2006;7:225. doi:10.1186/1471-2105-7-225. PMID:16640789
   PubMed Web of Science ®Google Scholar